Eli Lilly And Company (LLY): Today's Featured Drugs Winner
(
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.3%. By the end of trading, Eli Lilly and Company rose $0.55 (1.1%) to $51.13 on average volume. Throughout the day, 4,245,841 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5,365,400 shares. The stock ranged in a price between $50.66-$51.19 after having opened the day at $50.80 as compared to the previous trading day's close of $50.58. Other companies within the Drugs industry that increased today were:
(
), up 20.1%,
(
), up 15.5%,
(
), up 14.3% and
(
), up 11.8%.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $56.5 billion and is part of the health care sector. Shares are up 2.6% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Eli Lilly and Company a buy, 3 analysts rate it a sell, and 7 rate it a hold.
TheStreet Ratings rates
Eli Lilly and Company
as a
. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, increase in net income, largely solid financial position with reasonable debt levels by most measures, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow.
- You can view the full Eli Lilly and Company Ratings Report.
On the negative front,
(
), down 70.1%,
(
), down 37.2%,
(
), down 20.0% and
(
), down 10.3% , were all laggards within the drugs industry with
(
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null